New hope for kids with tough cancers: drug combo tested in small study

NCT ID NCT02512926

First seen Nov 01, 2025 · Last updated May 19, 2026 · Updated 28 times

Summary

This early-phase study tested a new drug, carfilzomib, combined with two standard chemotherapy drugs (cyclophosphamide and etoposide) in 4 children whose solid tumors or leukemia had returned or not responded to prior treatments. The main goal was to find the safest dose and understand side effects. The study was completed but did not aim to cure the disease; it focused on controlling the cancer and gathering safety information.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for REFRACTORY SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Alberta Children's Hospital

    Calgary, Alberta, T3B 6A8, Canada

  • Arkansas Children's Hospital

    Little Rock, Arkansas, 72202, United States

  • Dana Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • Memorial Sloan-Kettering Cancer Center

    New York, New York, 10065, United States

  • Penn State Hershey Children's Hospital

    Hershey, Pennsylvania, 17033-0850, United States

  • Phoenix Children's Hospital

    Phoenix, Arizona, 85016, United States

  • Stanford University School of Medicine and Stanford Cancer Institute

    Palo Alto, California, 94304, United States

  • University of Texas Health Science Center at San Antonio

    San Antonio, Texas, 78229, United States

Conditions

Explore the condition pages connected to this study.